Literature DB >> 6244079

CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme.

F Cianfriglia, A Pompili, A Riccio, A Grassi.   

Abstract

One hundred and three patients with hemispheric supratentorial glioblastoma multiforme were studied. All patients were operated on and a histologic diagnosis of glioblastoma multiforme was made. Patients were randomly placed in one of three treatment schedules within 3 weeks of surgery: Group A: combined radiation therapy and drug (CCNU) therapy (26 cases); Group B: CCNU given orally every 6-8 weeks (27 cases); Group C: standard radiation therapy alone (50 cases). All patients were periodically controlled by clinical and instrumental (EEG, scan, EMG, CAT) evaluations; laboratory data examinations were also frequently performed. The treatment results have been evaluated according to length of survival, social quality of life, and positive or negative response to chemotherapy. In our opinion the clinical findings are interesting but the statistical results are somewhat negative, especially when the groups of patients are not homogeneous.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244079     DOI: 10.1002/1097-0142(19800315)45:6<1289::aid-cncr2820450605>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.

Authors:  J C Tonn; R Schönmayr; H P Kraemer
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

3.  Measurements of the volume and density of intracerebral tumors by CT following therapy.

Authors:  K Kretzschmar; K H Schicketanz
Journal:  Neuroradiology       Date:  1982       Impact factor: 2.804

4.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

5.  Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.

Authors:  H J Eyre; J M Quagliana; J R Eltringham; J Frank; R M O'Bryan; B McDonald; S E Rivkin
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

Authors:  P Paoletti; G Butti; R Knerich; P Gaetani; R Assietti
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

7.  Immunological monitoring of patients affected by anaplastic glioma concerning in effects of surgery, radio-, and chemotherapy. A preliminary report.

Authors:  F Servadei; R Parente; F Spagnolli; G Gaist; R Padovani; M Bucci; L Steiner
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

8.  Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.

Authors:  P Lunardi; J Osman Farah; L Mastronardi; F Puzzilli; F M Lo Bianco
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 9.  Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.

Authors:  Brennan M R Spiegel; Eric Esrailian; Loren Laine; Marc C Chamberlain
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme.

Authors:  J Boëthius; H Blomgren; V P Collins; T Greitz; H Strander
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.